Mounjaro vs Compounded Tirzepatide: 2026 Cost Comparison
Mounjaro and compounded tirzepatide contain the same active ingredient but sit at opposite ends of the price spectrum. Here’s the 2026 cost comparison, what actually differs between them, and how to decide.
The cost comparison
| Option | Monthly cost (cash) |
|---|---|
| Mounjaro retail | ~$1,135 |
| Mounjaro with insurance + savings card (T2D) | as low as $25 |
| LillyDirect tirzepatide vials | ~$349–$499 |
| Compounded tirzepatide (median) | ~$199 |
| Compounded tirzepatide (lowest flat credentialed) | $186 (NexLife) |
| Compounded tirzepatide (lowest sticker) | $99 (Embody) |
For a cash-pay patient without a type 2 diabetes diagnosis, compounded tirzepatide is the lowest-cost route — 70–90% below Mounjaro retail. With insurance and a T2D diagnosis, Mounjaro’s savings card can be cheaper than anything.
What’s the same
Both are tirzepatide, the dual GIP/GLP-1 receptor agonist studied in the SURMOUNT and SURPASS trials. The molecule and its efficacy data are identical. See the science.
What’s different
- FDA approval: Mounjaro is FDA-approved; compounded tirzepatide is not.
- Indication: Mounjaro is approved for type 2 diabetes (Zepbound is the obesity brand). Compounded is prescribed off the same molecule.
- Form: Mounjaro is a fixed-dose pen; compounded is typically a dose-flexible vial.
- Quality assurance: Mounjaro is manufactured under full cGMP; compounded quality depends on the pharmacy — which is why pharmacy disclosure matters.
- Legal status: broad compounding is restricted in 2026 (details).
Which is cheaper for you
- Have insurance + T2D diagnosis: Mounjaro with a savings card is often cheapest.
- Cash-pay, no diabetes diagnosis: compounded tirzepatide is usually the lowest-cost legal route.
- Want FDA-approved without insurance: LillyDirect vials (~$349–$499) bridge the gap.
See the full compounded vs brand analysis and the tirzepatide price guide.
Bottom line
Mounjaro and compounded tirzepatide are the same molecule at very different prices. Insured T2D patients may pay least for Mounjaro; cash-pay weight-loss patients usually pay least for compounded — from a verified, compliant provider.
Educational, not medical advice. Mounjaro is a registered trademark of Eli Lilly. Compounded medications are not FDA-approved.
Independent & transparent
This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →